(secondQuint)Candin Safety & Efficacy Study for the Treatment of Warts.

 The primary objective of this study is to determine the safety of Candin(R) (Candida albicans Skin Test Antigen) at either 0.

3 mL dose levels at up to 6 monthly injections (a maximal, cumulative dose of 1.

9 mL, including the delayed-type hypersensitivity (DTH) test) for treating common warts (Verruca vulgaris).

 A secondary objective is to understand the relative effectiveness of the 0.

3 dose level for treating common warts, both those that were injected and those that were not injected as well as other types of warts that were not injected to allow a determination of appropriate dose levels to use in a future dose-ranging efficacy trial.

.

 Candin Safety & Efficacy Study for the Treatment of Warts@highlight

The primary objective of this study is to determine the safety of Candin(R) (Candida albicans Skin Test Antigen) at a 0.

3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).

